Saeromi Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saeromi Chung has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Yoon-Bo Shim
Pusan National University
8 shared publications - Drew A. Hall
University of California, San Diego
7 shared publications N.G. Gurudatt
Department of Chemistry and Institute of BioPhysio Sensor Technology, Pusan National University, Busan, 46241, Republic of Korea; National Efficacy Evaluation Center for Metabolic Disease Therapeutics, Lee Gil Ya Cancer and Diabetes Institute, Gil Medical Center, Gachon University, Incheon, 21565, Republic of Korea
2 shared publicationsNaveen K. Singh
Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California 92093, United States
2 shared publicationsA. Benboudiaf
Department of Chemistry and Institute of BioPhysio Sensor Technology (IBST) Pusan National University Busan 46241 South Korea
1 shared publication- Aditi Jain
Department of Electrical and Computer Engineering, University of California, San Diego, La Jolla, CA, USA
1 shared publication
Latest Publications
- 28 August 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Circuits and Systems
- Vol. 19 (2) , 416-427
An Electrochemical CMOS Biosensor Array Using Phase-Only Modulation With 0.035% Phase Error and In-Pixel Averaging
This paper presents a 16×20 CMOS biosensor array based on electrochemical impedance spectroscopy (EIS), a highly sensitive label-free technique for rapid disease detection at point-of-care. This high-density system implements a polar-mode detection with phase-only EIS measurement over a 5 kHz - 1 MHz frequency range. The design features predominantly digital readout circuitry, ensuring scalability with technology, along with a load-compensated transimpedance amplifier at the front, all within a 140×140 μm 2 ; pixel. The architecture enables in-pixel digitization and accumulation, which increases the SNR by 10 dB for each 10× increase in readout time. Implemented in a 180 nm CMOS process, the 3×4 mm 2 chip achieves state-of-the-art performance with an rms phase error of 0.035% at 100 kHz through a duty-cycle insensitive phase detector and one of the smallest per pixel areas with in-pixel quantization.
- 28 August 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Circuits and Systems
- Vol. 19 (2) , 416-427
An Electrochemical CMOS Biosensor Array Using Phase-Only Modulation With 0.035% Phase Error and In-Pixel Averaging
This paper presents a 16×20 CMOS biosensor array based on electrochemical impedance spectroscopy (EIS), a highly sensitive label-free technique for rapid disease detection at point-of-care. This high-density system implements a polar-mode detection with phase-only EIS measurement over a 5 kHz - 1 MHz frequency range. The design features predominantly digital readout circuitry, ensuring scalability with technology, along with a load-compensated transimpedance amplifier at the front, all within a 140×140 μm 2 ; pixel. The architecture enables in-pixel digitization and accumulation, which increases the SNR by 10 dB for each 10× increase in readout time. Implemented in a 180 nm CMOS process, the 3×4 mm 2 chip achieves state-of-the-art performance with an rms phase error of 0.035% at 100 kHz through a duty-cycle insensitive phase detector and one of the smallest per pixel areas with in-pixel quantization.
- 30 May 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Circuits and Systems
- Vol. 18 (4) , 756-770
Mitigating Medication Tampering and Diversion via Real-Time Intravenous Opioid Quantification
Opioid tampering and diversion pose a serious problem for hospital patients with potentially life-threatening consequences. The ongoing opioid crisis has resulted in medications used for pain management and anesthesia, such as fentanyl and morphine, being stolen, substituted with a different substance, and abused. This work aims to mitigate tampering and diversion through analytical verification of the administered drug before it enters the patient. We present an electrochemical-based sensor and miniaturized wireless potentiostat that enable real-time intravenous (IV) monitoring of opioids, specifically fentanyl and morphine. The proposed system is connected to an IV drip system during surgery or post-operation recovery. Measurement results of two opioids are presented, including calibration curves and data on the sensor performance concerning pH, temperature, interference, reproducibility, and long-term stability. Finally, we demonstrate real-time fluidic measurements connected to a flow cell to simulate IV administration and a blind study classified using a machine-learning algorithm. The system achieves limits of detection (LODs) of 1.26 μg/mL and 2.75 μg/mL for fentanyl and morphine, respectively, while operating with >1-month battery lifetime due to an optimized ultra-low power 36 μA sleep mode.
- 30 May 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Circuits and Systems
- Vol. 18 (4) , 756-770
Mitigating Medication Tampering and Diversion via Real-Time Intravenous Opioid Quantification
Opioid tampering and diversion pose a serious problem for hospital patients with potentially life-threatening consequences. The ongoing opioid crisis has resulted in medications used for pain management and anesthesia, such as fentanyl and morphine, being stolen, substituted with a different substance, and abused. This work aims to mitigate tampering and diversion through analytical verification of the administered drug before it enters the patient. We present an electrochemical-based sensor and miniaturized wireless potentiostat that enable real-time intravenous (IV) monitoring of opioids, specifically fentanyl and morphine. The proposed system is connected to an IV drip system during surgery or post-operation recovery. Measurement results of two opioids are presented, including calibration curves and data on the sensor performance concerning pH, temperature, interference, reproducibility, and long-term stability. Finally, we demonstrate real-time fluidic measurements connected to a flow cell to simulate IV administration and a blind study classified using a machine-learning algorithm. The system achieves limits of detection (LODs) of 1.26 μg/mL and 2.75 μg/mL for fentanyl and morphine, respectively, while operating with >1-month battery lifetime due to an optimized ultra-low power 36 μA sleep mode.
- Top Cited PapersOpen Access
- 29 January 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 227, 115097
A non-invasive wearable stress patch for real-time cortisol monitoring using a pseudoknot-assisted aptamer
- 29 January 2023
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 227, 115097
Top Cited PapersOpen AccessA non-invasive wearable stress patch for real-time cortisol monitoring using a pseudoknot-assisted aptamer
- Open Access
- 17 October 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (43) , 39097-39106
Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly personalized manner. We report an electrochemical conformation-changing aptasensor with two assay formats: a 30 min assay for routine monitoring and a 5 min assay for rapid emergency testing. To enable “sample-to-answer” testing, a de novo CBZ aptamer (Kd < 12 nM) with conformational switching due to a G-quadruplex motif was labeled with methylene blue and immobilized on a gold electrode. The electrode fabrication and detection conditions were optimized using electrochemical techniques and visualized by atomic force microscopy (AFM). The aptasensor performance, including reproducibility, stability, and interference, was characterized using electrochemical impedance spectroscopy and voltammetry techniques. The aptasensor exhibited a wide dynamic range in buffer (10 nM to 100 μM) with limits of detection of 1.25 and 1.82 nM for the 5 and 30 min assays, respectively. The clinical applicability is demonstrated by detecting CBZ in finger prick blood samples (<50 μL). The proposed assays provide a promising method to enable point-of-care monitoring for timely personalized CBZ dosing.
- 17 October 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (43) , 39097-39106
Open AccessElectrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care
Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient’s clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly personalized manner. We report an electrochemical conformation-changing aptasensor with two assay formats: a 30 min assay for routine monitoring and a 5 min assay for rapid emergency testing. To enable “sample-to-answer” testing, a de novo CBZ aptamer (Kd < 12 nM) with conformational switching due to a G-quadruplex motif was labeled with methylene blue and immobilized on a gold electrode. The electrode fabrication and detection conditions were optimized using electrochemical techniques and visualized by atomic force microscopy (AFM). The aptasensor performance, including reproducibility, stability, and interference, was characterized using electrochemical impedance spectroscopy and voltammetry techniques. The aptasensor exhibited a wide dynamic range in buffer (10 nM to 100 μM) with limits of detection of 1.25 and 1.82 nM for the 5 and 30 min assays, respectively. The clinical applicability is demonstrated by detecting CBZ in finger prick blood samples (<50 μL). The proposed assays provide a promising method to enable point-of-care monitoring for timely personalized CBZ dosing.
- Open Access
- 5 November 2021
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 414 (10) , 3187-3196
Point-of-care human milk testing for maternal secretor status
We present an electrochemical impedimetric-based biosensor for monitoring the variation in human milk oligosaccharide (HMO) composition. 2′-Fucosyllactose (2’FL) is an HMO associated with infant growth, cognitive development, and protection from infectious diarrhea, one of the major causes of infant death worldwide. Due to genetic variation, the milk of some women (non-secretors) contains no or very little 2′FL with potential implications for infant health and development. However, there is currently no technology to analyze the presence and concentration of HMOs in human milk at the point-of-care (POC). The lack of such technology represents a major impediment to advancing human milk research and improving maternal-infant health. Towards this unmet need, we report an impedimetric assay for HMOs with an α-1,2 linkage, the most abundant of which is 2′FL. The sensor uses a lectin for affinity, specifically Ulex europaeusagglutininI (UEA), with electrochemical readout. In spiked studies, the sensor exhibited a high degree of linearity (R2 = 0.991) over 0.5 to 3.0 μM with a 330-nM detection limit. The sensor performance was clinically validated using banked human milk samples and correctly identified all secretor vs. non-secretor samples. Furthermore, despite the short 35-min assay time and low sample volume (25 μL), the assay was highly correlated with HPLC measurements. This bedside human milk testing assay enables POC, “sample-to-answer” quantitative HMO measurement, and will be a valuable tool to assess milk composition. Graphical abstract
- 5 November 2021
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 414 (10) , 3187-3196
Open AccessPoint-of-care human milk testing for maternal secretor status
We present an electrochemical impedimetric-based biosensor for monitoring the variation in human milk oligosaccharide (HMO) composition. 2′-Fucosyllactose (2’FL) is an HMO associated with infant growth, cognitive development, and protection from infectious diarrhea, one of the major causes of infant death worldwide. Due to genetic variation, the milk of some women (non-secretors) contains no or very little 2′FL with potential implications for infant health and development. However, there is currently no technology to analyze the presence and concentration of HMOs in human milk at the point-of-care (POC). The lack of such technology represents a major impediment to advancing human milk research and improving maternal-infant health. Towards this unmet need, we report an impedimetric assay for HMOs with an α-1,2 linkage, the most abundant of which is 2′FL. The sensor uses a lectin for affinity, specifically Ulex europaeusagglutininI (UEA), with electrochemical readout. In spiked studies, the sensor exhibited a high degree of linearity (R2 = 0.991) over 0.5 to 3.0 μM with a 330-nM detection limit. The sensor performance was clinically validated using banked human milk samples and correctly identified all secretor vs. non-secretor samples. Furthermore, despite the short 35-min assay time and low sample volume (25 μL), the assay was highly correlated with HPLC measurements. This bedside human milk testing assay enables POC, “sample-to-answer” quantitative HMO measurement, and will be a valuable tool to assess milk composition. Graphical abstract
- Open Access
- 11 October 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (42) , 27888-27897
Cortisol Detection in Undiluted Human Serum Using a Sensitive Electrochemical Structure-Switching Aptamer over an Antifouling Nanocomposite Layer
- 11 October 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (42) , 27888-27897
Open AccessCortisol Detection in Undiluted Human Serum Using a Sensitive Electrochemical Structure-Switching Aptamer over an Antifouling Nanocomposite Layer
- Open Access
Development of a Soluble KIT (sKIT) Electrochemical Aptasensor For Cancer Theranostics
A conformational changing aptamer based electrochemical sensor was developed for the detection of soluble KIT, a cancer biomarker, in human serum. The sensor was fabricated with a ferrocene labeled aptamer ( K d < 5 nM) conjugated to a gold electrode. Quantitative KIT detection was performed using electrochemical impedance spectroscopy (EIS) and square wave voltammetry (SWV). The experimental parameters such as the ratio of aptamer to spacer, aptamer immobilization time, pH, and KIT incubation time were optimized by EIS, and the sensing surface was characterized with voltammetry. The assay specificity was investigated using interfering species showing high specificity towards the target protein. The aptasensor exhibited a wide dynamic range from 10 pg/mL to 100 ng/mL in buffer with a detection limit of 1.15 pg/mL. The sensor also exhibited a linear response with increased KIT concentrations spiked in human serum. The applicability of the sensor was successfully demonstrated using cancer cell conditioned media. The proposed aptasensor can be used in continuous or intermittent approach for cancer therapy monitoring and diagnostics (theranostics).
Open AccessDevelopment of a Soluble KIT (sKIT) Electrochemical Aptasensor For Cancer Theranostics
A conformational changing aptamer based electrochemical sensor was developed for the detection of soluble KIT, a cancer biomarker, in human serum. The sensor was fabricated with a ferrocene labeled aptamer ( K d < 5 nM) conjugated to a gold electrode. Quantitative KIT detection was performed using electrochemical impedance spectroscopy (EIS) and square wave voltammetry (SWV). The experimental parameters such as the ratio of aptamer to spacer, aptamer immobilization time, pH, and KIT incubation time were optimized by EIS, and the sensing surface was characterized with voltammetry. The assay specificity was investigated using interfering species showing high specificity towards the target protein. The aptasensor exhibited a wide dynamic range from 10 pg/mL to 100 ng/mL in buffer with a detection limit of 1.15 pg/mL. The sensor also exhibited a linear response with increased KIT concentrations spiked in human serum. The applicability of the sensor was successfully demonstrated using cancer cell conditioned media. The proposed aptasensor can be used in continuous or intermittent approach for cancer therapy monitoring and diagnostics (theranostics).
- 6 November 2019
- Published by Wiley in Electroanalysis
- Vol. 32 (3) , 520-527
A Sensor for Serotonin and Dopamine Detection in Cancer Cells Line Based on the Conducting Polymer−Pd Complex Composite
An electrochemical sensor based on the conducting polymer composite with a palladium complex (Pd(C2H4N2S2)2) was developed for the detection of serotonin and dopamine simultaneously in the breast cancer cell and human plasma samples. The proposed sensor was fabricated using the Pd(C2H4N2S2)2 complex‐anchored poly2,2 : 5,2‐terthiophene‐3‐(p‐benzoic acid) (pTBA) layer on the AuNPs decorated reduced graphene oxide (AuNPs@rGO) substrate, which revealed the enhanced anodic current of the target species. The sensor probe was characterized by electrochemical and surface analysis methods. The experimental parameters affecting the sensor performance were optimized, in terms of AuNPs@rGO concentration, the number of electropolymerization cycle for pTBA, immobilization time of Pd(C2H4N2S2)2, and pH. The dynamic ranges for serotonin and dopamine were obtained from 0.02 to 200 μM, and from 0.1 to 200 μM with the detection limit of 2.5, and 24.0 nM, respectively. The reliability of proposed sensor was evaluated using cancer cell lines for the clinical applications.
- 6 November 2019
- Published by Wiley in Electroanalysis
- Vol. 32 (3) , 520-527
A Sensor for Serotonin and Dopamine Detection in Cancer Cells Line Based on the Conducting Polymer−Pd Complex Composite
An electrochemical sensor based on the conducting polymer composite with a palladium complex (Pd(C2H4N2S2)2) was developed for the detection of serotonin and dopamine simultaneously in the breast cancer cell and human plasma samples. The proposed sensor was fabricated using the Pd(C2H4N2S2)2 complex‐anchored poly2,2 : 5,2‐terthiophene‐3‐(p‐benzoic acid) (pTBA) layer on the AuNPs decorated reduced graphene oxide (AuNPs@rGO) substrate, which revealed the enhanced anodic current of the target species. The sensor probe was characterized by electrochemical and surface analysis methods. The experimental parameters affecting the sensor performance were optimized, in terms of AuNPs@rGO concentration, the number of electropolymerization cycle for pTBA, immobilization time of Pd(C2H4N2S2)2, and pH. The dynamic ranges for serotonin and dopamine were obtained from 0.02 to 200 μM, and from 0.1 to 200 μM with the detection limit of 2.5, and 24.0 nM, respectively. The reliability of proposed sensor was evaluated using cancer cell lines for the clinical applications.
- 1 October 2018
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 117, 480-486
Magnetic force assisted electrochemical sensor for the detection of thrombin with aptamer-antibody sandwich formation
- 1 October 2018
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 117, 480-486
Magnetic force assisted electrochemical sensor for the detection of thrombin with aptamer-antibody sandwich formation